From:
`Sent:
`To:
`Cc:
`Subject:
`
`Arnold, Jeffery <JArnold@CantorColburn.com>
`Monday, July 11, 2016 12:34 PM
`Reister, Andrea; Ryan, Andrew
`Fox, Harold; Weeks, Dustin B.; Ladow, Daniel A. (Daniel.Ladow@troutmansanders.com)
`RE: IPR2016-01111, -01112, -01113
`
`Hello Andrea,
`
`This message is to recap our meet and confer telephone conference which occurred 6 July 2016. It
`was surprising that the meet and confer was more akin to a deposition. We had incorrectly anticipated
`a discussion regarding a motion to seek discovery. Nevertheless, I cooperated to a point in order to
`explain that Petitioners were not time-barred from filing the respective subject petitions and avoid
`adding to the board’s workload with a time-consuming discovery motion.
`
`During the teleconference, you referenced the footnoted article below and asked if Petitioners had an
`agreement with Teva and/or Allergan regarding their respective Suboxone-related ANDAs. I stated
`that the article was speculative regarding the two drugs mentioned therein. Additionally, I stated that
`I was without authority to confirm or deny that the agreement between Teva and Petitioners includes
`Teva’s and/or Allergan’s Suboxone related ANDAs. That position remains unchanged.
`
`You were also informed:
`
`
` At the time the respective complaints against Teva and Allergan were filed, Petitioners were
`neither a real-party-in-interest nor had any control over such litigation, which remains true as
`of the date of this email. For verification, review the respective Suboxone litigation dockets for
`mandatory disclosures of real-parties-in-interest. No such document exists identifying
`Petitioners.
`o In furtherance to the above proffer, on 27 June 2016, Mr. Ladow via email asked for “the
`name and contact information for the appropriate Dr. Reddy’s in-house counsel to
`whom Indivior’s GC, Javier Rodriguez, can direct settlement –related communications.”
`Via 28 June 2016 email, I provided Dr. Anjum Swaroop’s contact information and asked
`if Mr. Rodriguez would be representing both Monosol Rx, LLC and Indivior (Patent
`Owners) in the proposed communications? In response to Mr. Rodriguez’ 29 June 2016
`email to Dr. Swaroop requesting a date and time “to discuss ongoing ANDA litigation,”
`Dr. Swroop responded in her 30 June 2016 email that “DRL is not involved in the
`Suboxone litigation at this time. At this time, DRL is not a real party-in-interest in nor
`has any control over the current ligation between Indivior and any defendants involving
`Suboxone.” The meeting was scheduled for 5 July 2016, but abruptly canceled without
`comment by Mr. Rodriguez. You should be able to get these communications directly
`from Messrs. Ladow and Rodriguez.
` At the time the three IPRs were filed, there was no privity between Teva and/or Allergan or
`control by DRL over Suboxone ANDA litigation in which Teva and Allergan are respective
`defendants.
` At the time the three IPRs were filed, there was no agreement of any kind between Teva and/or
`Allergan and Petitioners with respect to Teva’s and/or Allergan’s respective Suboxone ANDAs.
` There was no communication between Teva or its counsel and Petitioners or Cantor Colburn
`regarding Petitioners’ three IPR petitions prior to filing.
`
`1
`
`MonoSol2005-0001
`
`Dr. Reddys v. MonoSol
`IPR2016-01112
`
`

`
`o As of the date of this email, there has been no such communications directed to the IPR
`petitions subsequent to filing.
` Teva has no interest in or control over the respective IPRs petitioned by Petitioners.
`o For verification, see the respective IPR petitions identifying Petitioners as the “real-
`parties-in-interest.”
` You asked if Teva was providing funding for the three IPRs. Petitioners are self-funding the
`subject IPRs. Neither Teva nor Allergan were or are obligated to fund the subject IPRs on
`behalf of Petitioners.
`o Again, see the respective IPR petitions identifying Petitioners as the “real-parties-in-
`interest.”
` Teva provided no guidance on the preparation and filing of Petitioners’ IPR petitions.
` The subject IPR petitions are directed solely by Petitioners, no other party is involved with
`Petitioners. I believe I said that the “petitions are all Dr. Reddy’s and no one else.”
`
`
`Please let us know if you disagree with or have anything to add to the above recap. Also, if you have
`any further questions on this topic, please submit them in writing.
`
`Regards,
`
`Jeff
`
`
`
`Jeffery B. Arnold 
`Partner 
`
` 
`
`1180 Peachtree St., N.E. | Suite 2050 | Atlanta, GA  30309 
`Work: 404‐607‐9991, ext. 2127 | Fax: 404‐607‐9981 | Mobile: 404‐665‐7311 
`jarnold@cantorcolburn.com 
`www.cantorcolburn.com 
`
`HARTFORD    WASHINGTON, D.C.    ATLANTA    HOUSTON    DETROIT 
`
`From: Reister, Andrea [mailto:areister@cov.com]
`Sent: Monday, June 27, 2016 7:43 PM
`To: Arnold, Jeffery; Ryan, Andrew
`Cc: Fox, Harold; Weeks, Dustin B.
`Subject: RE: IPR2016-01111, -01112, -01113
` 
`Jeff,
`
`Many thanks for the prompt reply. Let’s plan on 2:00 PM on July 6, 2016. We can use the following
`conference call information.
`
`1.800.851.0297
`Access Code 2402458
`
`Regards,
`
`Andrea G. Reister
`
`2
`
`MonoSol2005-0002
`
`

`
`
`Covington & Burling LLP
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001-4956
`T +1 202 662 5141 | areister@cov.com
`www.cov.com
`
`
`
`
`
`
`From: Arnold, Jeffery [mailto:JArnold@CantorColburn.com]
`Sent: Monday, June 27, 2016 4:28 PM
`To: Reister, Andrea; Ryan, Andrew
`Cc: Fox, Harold; Weeks, Dustin B.
`Subject: RE: IPR2016-01111, -01112, -01113
` 
`Hello Ms. Reister, 
`
` 
`We are available between 2-5 p.m. 6 July to meet and confer. 2 p.m. works for us. 
`
` 
`Regards, 
`
` 
`Jeff 
`  
`Jeffery B. Arnold 
`Partner 
`
` 
`
`1180 Peachtree St., N.E. | Suite 2050 | Atlanta, GA  30309 
`Work: 404‐607‐9991, ext. 2127 | Fax: 404‐607‐9981 | Mobile: 404‐665‐7311 
`jarnold@cantorcolburn.com 
`www.cantorcolburn.com 
`
`HARTFORD    WASHINGTON, D.C.    ATLANTA    HOUSTON    DETROIT 
`
` 
`From: Reister, Andrea [mailto:areister@cov.com]
`Sent: Monday, June 27, 2016 10:29 AM
`To: Arnold, Jeffery; Hagerty, Peter; Maxwell, Anne; Ryan, Andrew
`Cc: Fox, Harold; Weeks, Dustin B.
`Subject: IPR2016-01111, -01112, -01113 
`
`  
`Counsel, 
`
` 
`We are counsel for the above-noted IPR proceedings, and write regarding a meet and confer to
`discuss discovery related to Dr. Reddy’s Laboratories’ “definitive agreement with Teva
`Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and an affiliate of Allergan plc
`(NYSE: AGN) to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in
`the U.S. for $350 million in cash at closing.” Press Release, Dr. Reddy’s Laboratories Ltd., Dr.
`Reddy’s to acquire product portfolio from TEVA for US Market (June 11, 2016). Analysts have
`reported that one of “the products Dr. Reddy’s acquired [was] related to Indivior Plc.’s opioid
`dependence treatment Suboxone.”[1] Whether and how Dr. Reddy’s acquired either Teva’s or
`Allergan’s (d/b/a Actavis) interest in those ANDAs related to Suboxone is highly relevant to the
`
`3
`
`MonoSol2005-0003
`
`

`
`above-captioned proceeding as both Teva and Actavis are time-barred from initiating this
`proceeding under 35 U.S.C. § 315(b).  
`
` 
`We are available on July 6, 2016, from 2:00 PM to 5:00 PM Eastern time. Please let us know
`what time works best for you, and we will circulate a dial-in number for the call. 
`
`Andrea G. Reister
`
`Covington & Burling LLP
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001-4956
`T +1 202 662 5141 | areister@cov.com
`www.cov.com
`
`
` 
`[1] Suryatapa Bhattacharya, Dr. Reddy’s Buying Eight Drugs From Teva for U.S. Market, Wall
`Street Journal, June 13, 2016, http://www.wsj.com/articles/dr-reddys-buying-eight-drugs-
`from-teva-for-u-s-market-1465666107.  
`
`  
`
`[1] Viswanath Pilla, Dr Reddy’s to launch 4 products acquired from Teva by FY18, Livemint, June 14, 2016, 
`http://www.livemint.com/Companies/ACzQxHrxnV3ClcaJ8XSfNO/Dr‐Reddys‐to‐launch‐4‐products‐acquired‐from‐Teva‐by‐
`FY18.html. 
`
`This transmission, and any attached files, may contain information from the law firm of Cantor Colburn LLP which is confidential and/or legally privileged. 
`Such information is intended only for the use of the individual or entity to whom this transmission is addressed. If you are not the intended recipient, you 
`are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this transmitted information is 
`strictly prohibited, that copies of this transmission and any attached files should be deleted from your disk directories immediately, and that any printed 
`copies of this transmission or attached files should be returned to this firm. If you have received this transmission in error, please notify us by telephone or 
`e‐mail immediately, and we will arrange for the return to Cantor Colburn LLP of any printed copies.  
`
`4
`
`MonoSol2005-0004